ARID1A is a recently identified tumor suppressor gene that is mutated in approximately 50% of ovarian clear cell and 30% of ovarian endometrioid carcinomas. The mutation is associated with loss of protein expression as assessed by immunohistochemistry. In this study, we evaluated ARID1A immunoreactivity in a wide variety of carcinomas to determine the prevalence of ARID1A inactivation in carcinomas. Mutational analysis of ARID1A was carried out in selected cases. Immunoreactivity was not detected (corresponding to inactivation or mutation of ARID1A) in 36 (3.6%) of 995 tumors. Uterine low-grade endometrioid carcinomas showed a relatively high-frequency loss of ARID1A expression, as 15 (26%) of 58 cases were negative. The other tumor that had a relatively highfrequency loss of ARID1A expression was gastric carcinoma (11%). Mutational analysis showed 10 (40%) of 25 uterine endometrioid carcinomas; none of 12 uterine serous carcinomas and none of 56 ovarian serous and mucinous carcinomas harbored somatic ARID1A mutations. All mutations in endometrioid carcinomas were nonsense or insertion/deletion mutations, and tumors with ARID1A mutations showed complete loss or clonal loss of ARID1A expression. In conclusion, this study is the first large-scale analysis of a wide variety of carcinomas showing that uterine low-grade endometrioid carcinoma is the predominant tumor type harboring ARID1A mutations and frequent loss of ARID1A expression. These findings suggest that the molecular pathogenesis of lowgrade uterine endometrioid carcinoma is similar to that of ovarian low-grade endometrioid and clear cell carcinoma, tumors that have previously been shown to have a highfrequency loss of expression and mutation of ARID1A.
Abstract: ARID1A is a recently identified tumor suppressor gene that is mutated in approximately 50% of ovarian clear cell and 30% of ovarian endometrioid carcinomas. The mutation is associated with loss of protein expression as assessed by immunohistochemistry. In this study, we evaluated ARID1A immunoreactivity in a wide variety of carcinomas to determine the prevalence of ARID1A inactivation in carcinomas. Mutational analysis of ARID1A was carried out in selected cases. Immunoreactivity was not detected (corresponding to inactivation or mutation of ARID1A) in 36 (3.6%) of 995 tumors. Uterine low-grade endometrioid carcinomas showed a relatively high-frequency loss of ARID1A expression, as 15 (26%) of 58 cases were negative. The other tumor that had a relatively highfrequency loss of ARID1A expression was gastric carcinoma (11%). Mutational analysis showed 10 (40%) of 25 uterine endometrioid carcinomas; none of 12 uterine serous carcinomas and none of 56 ovarian serous and mucinous carcinomas harbored somatic ARID1A mutations. All mutations in endometrioid carcinomas were nonsense or insertion/deletion mutations, and tumors with ARID1A mutations showed complete loss or clonal loss of ARID1A expression. In conclusion, this study is the first large-scale analysis of a wide variety of carcinomas showing that uterine low-grade endometrioid carcinoma is the predominant tumor type harboring ARID1A mutations and frequent loss of ARID1A expression. These findings suggest that the molecular pathogenesis of lowgrade uterine endometrioid carcinoma is similar to that of ovarian low-grade endometrioid and clear cell carcinoma, tumors that have previously been shown to have a highfrequency loss of expression and mutation of ARID1A. A cquisition of somatic mutations is a molecular hallmark of neoplasia. Sequence mutations that are acquired during tumor evolution can lead to activation of oncogenes and inactivation of tumor suppressor and DNA repair genes, thereby propelling tumor development and progression. 8 Identification and characterization of somatic mutations are not only fundamental in understanding the molecular pathogenesis of cancer but also can provide the rationale for the development of personalized diagnostic tests and therapy. With the use of whole exome sequencing and transcriptome sequencing, 2 independent studies recently reported ARID1A (also known as BAF250A) mutations in 43% to 56% of ovarian clear cell carcinomas and 30% of ovarian lowgrade endometrioid carcinomas 6, 21 but not in matched controls, confirming the somatic nature of the mutations. As both these tumor types are believed to be derived from endometriosis and because 1 of these studies also found ARID1A mutations in adjacent atypical endometriosis, it is conceivable that ARID1A loss is a relatively specific molecular event in the genesis of these tumors. Many ARID1A mutations are insertion/deletion mutations, leading to the generation of premature stop codons by frameshift that result in truncated proteins prone to degradation. It has been previously shown that loss of ARID1A expression, as assessed by immunohistochemistry (IHC), correlates closely with ARID1A mutations. 11, 21 ARID1A is located in the chromosome 1p36 region, and encodes a large nuclear protein involved in chromatin remodeling. ARID1A interacts with several other proteins including the core protein, BRG or BRM with ATPase activity. 4, 20 The ARID1A-BRG/BRM complex belongs to the SWI/SNF chromatin remodeling complex; remodeling activity is facilitated by ATP hydrolysis of BRG or BRM. In contrast, the noncatalytic subunits of the SWI/ SNF complex, such as ARID1A, are responsible for modulating the target specificity and activity of the ATPase. The chromatin remodeling activity of SWI/SNF has been shown to play an integral role in controlling gene expression 19 and is critical in tissue development, cellular differentiation, and tumor suppression. 3, 4, 15 AR-ID1A is essential for SWI/SNF complexes to suppress DNA synthesis. Inactivation of ARID1A is thought to enhance cell cycle progression by potentially involving c-myc, thereby contributing to uncontrolled cellular proliferation in cancer cells. 5, 13, 14 Although ARID1A has emerged as a new cancerassociated gene, which is frequently mutated in endometriosis-related ovarian neoplasms, it is not known whether its mutation, such as FOXL2 10,17 and APC, 9 is detected only in specific types of cancer or mutations, such as TP53 and KRAS, which occurs in a variety of neoplastic diseases. As ARID1A mutations are randomly distributed in 20 exons and are the insertion/deletion type of mutations that lead to truncated proteins, we used loss of ARID1A immunoreactivity as a surrogate marker for a mutation to screen a variety of carcinomas. Sequence analysis was then carried out in the specimens that showed the highest frequency of loss of ARID1A expression. For mutation analysis, genomic DNA isolated from affinity purified tumor samples was used. Those samples included 25 uterine endometrioid carcinomas (International Federation of Gynecology and Obstetrics grade 1), 12 uterine serous carcinomas, 32 ovarian high-grade serous carcinomas, 19 ovarian low-grade serous carcinomas, and 5 ovarian mucinous carcinomas. As the ARID1A mutation status has been previously reported in ovarian clear cell and ovarian low-grade endometrioid carcinomas, 6,11,21 these carcinomas were not included in this study. The methodology for the isolation of tumor cells from fresh carcinoma specimens has been previously described. 6 IHC IHC analysis was carried out on tissue microarrays except for 20 uterine endometrioid carcinomas and 33 renal cell carcinomas, which were carried out on wholetissue sections. Loss of ARID1A expression detected in the tissue microarrays was confirmed on whole-tissue sections. A polyclonal rabbit anti-ARID1A antibody (Sigma-Aldrich HPA005456) was generated by immunizing a rabbit with the following peptide sequence: PGLGNVAMGPRQHYPYGGPYDRVRTEPGIGPEG NMSTGAPQPNLMPSNP DSGMYSPSRYPPQQQQQQ QQRHDSYGNQFSTQGTPSGSPFPSQQTTMYQQQQ QNYK. The specificity of the antibody was confirmed by Western blotting. Antigen retrieval was performed by placing sections in a citrate buffer (pH 6.0), which were then placed in an autoclave at 1201C for 10 minutes. The sections were incubated with the rabbit antibody overnight at 41C. A positive reaction was detected by the EnVision+System (Dako, Carpinteria, CA). Tumor stromal cells served as positive internal controls. Only nuclear staining was scored. A previous study showed that loss of nuclear expression correlated with mutation of the gene. Hence, absence of nuclear staining (diffuse or focal) was considered to be positive for gene mutation.
MATERIALS AND METHODS

Tissue Material
Mutation Analysis
A total of 93 tumor samples were analyzed for somatic ARID1A mutations. The normal tissues from the matched cases were also sequenced in parallel. Nucleotide sequences of polymerase chain reaction primers that amplified exon 1 to exon 20 were previously reported. 6 Polymerase chain reaction products were prepared and purified for Sanger sequencing.
Gene Knockdown and Western Blot
The lentivirus-expressing ARID1A short hairpin ribonucleic acids (shRNAs) were produced using HEK293FT cells transfected with the pLKO.1-puro lentiviral plasmids (the RNAi consortium) and the second generation packaging system, pSPAX2 (Addgene plasmid 12260) and pMD2.G (Addgene plasmid 12259). The shRNA sequences were: shRNA1, GCCTGATCTATCT GGTTCAAT; shRNA2, CCTCTCTTATACACAGCA GAT; and shRNA3, CCGTTGATGAACTCATTGGTT. HeLa cells were transduced with lentiviral particles, and lysates in Laemmli sample buffer were prepared from the cells 3 days after transduction. For Western blots, SDS-PAGE was used to separate proteins that were then transferred onto PVDF membranes. The rabbit anti-ARID1A antibody as used in IHC was used to hybridize the membranes (at a dilution of 1:2000), and anti-GAPDH antibody was also applied to detect the GAPDH, serving as the loading control. After incubating at room temperature for 2 hours, the membranes were washed with TBST (0.01% Tween 20 in tris-buffered solution) and were blotted with HRP-conjugated antirabbit antibodies (Pierce, Rockford, IL) at a dilution of 1:1000 for 1 hour at room temperature. ARID1A and GAPDH bands were shown by chemiluminescence (Arlington Heights, IL).
RESULTS
A total of 995 carcinomas from a variety of tissue origins were studied for ARID1A expression using IHC. To confirm the specificity of the anti-ARID1A antibody used in this study, we performed a gene knockdown experiment by transducing HeLa cells with 3 different ARID1A shRNAs. Western blot analysis showed a significant decrease of ARID1A protein in HeLa cells after treatment with ARID1A-specific shRNAs, especially the shRNA-2 and shRNA-3 compared with control shRNA, indicating the specificity of the ARID1A antibody ( Fig. 1 ). Previous studies have shown that inactivating mutations of ARID1A are associated with loss of protein expression. 11, 21 Therefore, we focused our attention on those tumors with undetectable ARID1A immunoreactivity, and used a scoring system to classify all cases into ARID1A-negative (undetectable) and ARID1Apositive cases, which showed any levels of ARID1A immunoreactivity. As the ARID1A mutation status has been previously reported in ovarian clear cell and ovarian endometrioid carcinomas, 6,11,21 these carcinomas were not included in this study.
There was loss of expression of ARID1A in 34 (3.4%) of 995 cases. Stromal cells in these cases were positive for ARID1A immunoreactivity, indicating that the negative staining in tumor cells was not due to technical artifacts. The immunostaining findings for each tumor type are summarized in Table 1 and representative cases illustrated in Figure 2 . Specifically, among 21 types of carcinoma in this study, uterine low-grade endometrioid carcinomas showed loss of expression in 15 (26%) of 58 cases. In contrast, all the normal endometrial tissues examined in this study together with 38 normal endometrial tissues analyzed in our previous study 11 were intensely positive for ARID1A. In addition to uterine lowgrade endometrioid carcinomas, gastric carcinomas were negative for ARID1A expression in 11% of cases. We also observed that some carcinomas, especially uterine lowgrade endometrioid carcinomas, exhibited "clonal loss" of ARID1A immunoreactivity. This means that in a background of ARID1A-positive tumor cells, large groups of tumor cells did not express ARID1A (Fig. 3) . Although several other tumor types including carcinomas of the bile duct, lung, breast, uterine cervix, colon, and pancreas contained at least 1 case with negative ARID1A staining, the frequency of negative cases was very low (<10% of cases in each tumor type). In contrast, ARID1A was expressed in virtually all the epithelial cells in all normal adult and embryonic tissues tested which included breast, prostate, gastrointestinal tract, pancreas, bile duct, mullerian duct including endometrium (both premenopausal and postmenopausal), skin, respiratory tract, urinary tract, and trophoblast. In addition, lymphoblasts in the germinal center, smooth muscle cells, skeletal muscle cells, and endothelial cells were also positive for ARID1A.
Mutational analysis was carried out on uterine low-grade endometrioid carcinomas because they showed the highest frequency of loss of ARID1A expression. Nineteen ovarian low-grade, 32 ovarian high-grade, 5 ovarian mucinous, and 12 uterine serous carcinomas were also analyzed, none of which showed loss of ARID1A expression. As shown in Table 2 , somatic ARID1A mutation was detected in 10 (40%) of 25 uterine lowgrade endometrioid carcinomas. As in ovarian clear cell and ovarian endometrioid carcinomas, the mutations were either insertion/deletion mutations or nonsense mutations that were widely distributed in the ARID1A gene ( Table 3 ). Three of these 10 cases (UEM-1, UEM-5, and UEM-8) showed 2 independent ARID1A mutations, likely affecting both alleles. Correlation of ARID1A mutation status and immunoreactivity was made in 25 uterine endometrioid carcinomas and 51 ovarian serous carcinomas. We found that 5 (50%) of 10 tumors with ARID1A mutations did not show any detectable level of ARID1A immunoreactivity. Interestingly, 4 ARID1Apositive cases with ARID1A mutations exhibited a pattern of immunoreactivity in which areas of negative cells were present adjacent to positive areas suggesting that mutations arose in clones within the tumor (Fig. 3) . In contrast, only 2 of 15 ARID1A wild-type endometrioid carcinomas showed complete loss of ARID1A staining, whereas the majority of cases showed diffuse ARID1A staining (>80% of tumor cells being positive). We did not observe any pattern of clonal loss in ARID1A wildtype carcinomas as in ARID1A-mutated cases. All 19 ovarian low-grade serous carcinomas and 32 ovarian high-grade serous carcinomas showed diffuse ARID1A positivity; neither the above-mentioned carcinomas nor the 5 ovarian mucinous carcinomas contained ARID1A mutations ( Table 2) . Thus, the complete loss of ARID1A expression significantly correlated with its mutation status (P = 0.0014, Fisher exact test). Combining cases that were completely negative with those showing clonal loss and correlating them with ARID1A mutation was found to be highly significant (P<0.0001, Fisher exact test).
DISCUSSION
In the past few years, substantial progress has been made in cataloging molecular genetic alterations at a genome-wide scale. One of the main findings has been the identification of somatic mutations of several chromatin-remodeling genes in certain types of human cancer. These genes include JARID1C in renal cell carcinoma, 1 BRG1 (SMARCA4) in lung carcinoma, 12, 16 and, most recently, ARID1A in ovarian clear cell and ovarian low-grade endometrioid carcinoma. 6, 21 The findings in this study extend previous observations and provide cogent evidence that epigenetic changes, like genetic alteration, is a "driver" rather than a "passenger" that is directly involved in the tumor development of uterine low-grade endometrioid carcinoma. 7 In this study, a large number and variety of normal and tumor tissues were evaluated. The main findings were the loss of ARID1A immunoreactivity and mutation of ARDIA in low-grade uterine endometrioid carcinoma compared with other types of carcinomas. Although loss of ARID1A expression also occurs in other tumor types, the frequency of loss of expression is low, indicating that ARID1A mutations are associated with specific types of carcinoma. Mutational analysis showed somatic ARID1A mutations in 40% of uterine endometrioid carcinoma, a finding that has not been previously reported.
Endometrial carcinomas are divided into 2 broad groups, designated as type I and type II. Type I tumors are composed of endometrioid carcinomas that frequently harbor sequence mutations in CCNB1, PTEN, and PIK3CA, whereas type II tumors are largely serous carcinomas that contain TP53 mutations in the majority of cases. 2 Patients with type I tumors are usually younger, present at an earlier clinical stage, and have a more indolent clinical course compared with women with type II tumors. Type I tumors arise from endometrial hyperplasia, and type II tumors develop from endometrial intraepithelial carcinoma that is frequently associated with endometrial polyps. Thus, the relatively frequent loss of ARID1A expression and ARID1A mutations in uterine endometrioid carcinoma but not in uterine serous carcinoma further supports their distinct pathogenesis. Given the well-established roles of the Pten-AKT pathway and the Wnt pathway in the development of lowgrade uterine endometrioid carcinoma (type I tumor), it will be important to determine whether the ARID1A pathway cross talks with those signaling pathways and to assess how inactivation of ARID1A contributes to tumor initiation and progression in this type of carcinoma.
Although ARID1A mutations were most often associated with complete loss of its protein expression in low-grade uterine endometrioid carcinoma, we observed several uterine endometrioid carcinomas with ARID1A mutations that showed a heterogeneous staining pattern. In these cases, there were significantly large areas LG, low grade.
that were negative in what were otherwise positive cases. This geographic distribution of loss of ARID1A expression strongly suggests that ARID1A mutation occurred in clones of cells within the tumor. This type of clonal loss of ARID1A immunoreactivity was only detected in uterine endometrioid carcinomas with ARID1A mutations but not in those without mutations. It is likely that ARID1A mutations occur after tumor initiation in endometrioid carcinoma, creating tumor subclones during evolution of the carcinoma. It is of great interest to study ARID1A immunostaining patterns in endometrial hyperplasia to determine how early ARID1A protein is lost during tumor progression of endometrioid carcinoma. Similar to endometrial carcinoma, ovarian epithelial carcinomas have been divided into type I and type II categories based on their distinctive clinicopathologic and molecular features. 18 Ovarian clear cell carcinoma and low-grade ovarian endometrioid carcinoma comprise the majority of type I ovarian tumors and are frequently associated with endometriosis. The results from this study along with our previous reports 6, 11, 21 strongly suggest that loss of ARID1A expression and/or its mutations are largely confined to ovarian clear cell and ovarian endometrioid carcinomas, because the high-grade and low-grade serous carcinomas and mucinous carcinomas did not show ARID1A mutations or loss of expression. It is, therefore, conceivable that ARID1A mutation plays an important role in the development of ovarian tumors derived from endometriosis. As it is generally thought that endometriosis develops from retrograde menstruation, the underlying critical molecular event for the development of uterine low-grade endometrioid, ovarian endometrioid, and clear cell carcinomas in some cases is mutation of ARIDIA in the endometrial tissue. Although we did not detect ARID1A mutation in ovarian mucinous carcinomas, the small number of mucinous carcinomas analyzed in this study precludes a definitive conclusion regarding them.
In conclusion, based on ARID1A IHC and mutational analysis, we found that ARID1A inactivation, either by somatic mutations or by loss of expression, frequently occurs in uterine low-grade endometrioid carcinomas in addition to ovarian low-grade endometrioid and ovarian clear cell carcinomas. Thus, it seems that ARID1A inactivation is mainly confined to certain types of gynecologic cancers that arise from endometrial tissue, either from the uterine cavity or from an ectopic site, that is, endometriosis. This therefore leads to the conclusion that these endometrium-related tumors share a similar molecular pathogenesis. Our findings also support the use of complete loss or clonal loss of ARID1A immunoreactivity as a surrogate marker to detect ARID1A mutations in tissues. However, further studies are necessary to determine the role of ARID1A in the differential diagnosis. It would be also interesting to determine the mutation status and immunoreactivity of ARID1A in uterine high-grade endometrioid carcinoma and clear cell carcinoma.
